Tasly Pharmaceutical Group Co., Ltd (SHA:600535)

SHA:600535 Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Operating Revenue	8,316	8,468	8,636	8,606	7,898	13,505
Other Revenue	29.81	29.81	37.71	31.19	53.86	70.82
Revenue	8,346	8,498	8,674	8,637	7,952	13,576
Revenue Growth (YoY)	-2.56%	-2.03%	0.42%	8.62%	-41.43%	-28.54%
Cost of Revenue	2,747	2,810	2,885	3,147	2,682	8,115
Gross Profit	5,599	5,688	5,789	5,490	5,269	5,461
Selling, General & Admin	3,400	3,334	3,326	3,267	3,339	3,215
Research & Development	818.73	830.07	917.27	845.34	579.53	689.33
Other Operating Expenses	105.88	87.98	96.46	37.96	110.64	104.05
Operating Expenses	4,324	4,252	4,348	4,149	4,027	4,073
Operating Income	1,275	1,436	1,441	1,341	1,243	1,388
Interest Expense	-1.07	-61.28	-82.52	-64.86	-77.39	-286.69
Interest & Investment Income	18.45	91.05	107.55	107.55	1,792	241.04
Currency Exchange Gain (Loss)	-1.07	-1.07	-1.23	-1.61	7.27	5.58
Other Non Operating Income (Expenses)	0.66	-3.52	-4.73	-71.11	0	-11.05
EBT Excluding Unusual Items	1,292	1,461	1,460	1,311	2,965	1,337
Impairment of Goodwill	-15.88	-15.88	-	-151.2	-	-59.01
Gain (Loss) on Sale of Investments	59.71	-213.45	-282.81	-1,125	-79.88	118.21
Gain (Loss) on Sale of Assets	9.19	2.11	0.15	-4.93	41.27	-5.67
Asset Writedown	-162.96	-202.13	-1.78	-194.64	-262.53	-
Other Unusual Items	43.01	36.78	45.51	-1.96	60.04	66.91
Pretax Income	1,225	1,069	1,221	-167.63	2,724	1,457
Income Tax Expense	201.42	209.63	204.46	180.82	315.92	367.2
Earnings From Continuing Operations	1,023	859.06	1,017	-348.46	2,408	1,090
Minority Interest in Earnings	74.3	96.53	54.43	84.22	-48.75	36.03
Net Income	1,098	955.59	1,071	-264.24	2,359	1,126
Net Income to Common	1,098	955.59	1,071	-264.24	2,359	1,126
Net Income Growth	24.60%	-10.78%	-	-	109.51%	12.43%
Shares Outstanding (Basic)	1,479	1,494	1,488	1,468	1,502	1,501
Shares Outstanding (Diluted)	1,479	1,494	1,488	1,468	1,502	1,501
Shares Change (YoY)	-1.35%	0.43%	1.34%	-2.29%	0.08%	-1.06%
EPS (Basic)	0.74	0.64	0.72	-0.18	1.57	0.75
EPS (Diluted)	0.74	0.64	0.72	-0.18	1.57	0.75
EPS Growth	26.30%	-11.16%	-	-	109.33%	13.64%
Free Cash Flow	1,236	1,450	1,907	1,875	2,229	1,382
Free Cash Flow Per Share	0.84	0.97	1.28	1.28	1.48	0.92
Dividend Per Share	0.200	0.530	0.330	0.330	0.330	0.330
Dividend Growth	-69.70%	60.61%	-	-	-	-
Gross Margin	67.08%	66.94%	66.74%	63.56%	66.27%	40.23%
Operating Margin	15.27%	16.90%	16.61%	15.52%	15.63%	10.22%
Profit Margin	13.15%	11.24%	12.35%	-3.06%	29.66%	8.29%
Free Cash Flow Margin	14.81%	17.06%	21.98%	21.71%	28.04%	10.18%
EBITDA	1,590	1,832	1,946	1,774	1,648	1,927
EBITDA Margin	19.05%	21.56%	22.43%	20.54%	20.72%	14.20%
D&A For EBITDA	314.91	396.34	504.91	433.92	405.08	539.67
EBIT	1,275	1,436	1,441	1,341	1,243	1,388
EBIT Margin	15.27%	16.90%	16.61%	15.52%	15.63%	10.22%
Effective Tax Rate	16.44%	19.62%	16.74%	-	11.60%	25.20%
Revenue as Reported	2,036	8,498	8,674	8,637	-	13,576

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.